GLIOSARCOMA
Clinical trials for GLIOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new GLIOSARCOMA trials appear
Sign up with your email to follow new studies for GLIOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for glioblastoma? early trial combines drug with radiation
Disease control OngoingThis early-phase trial tests a new drug called Peposertib, combined with radiation and chemotherapy, for people with a hard-to-treat type of brain cancer called glioblastoma. The study aims to find the best dose and check safety in 29 participants. If it works, the drug may help …
Matched conditions: GLIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Laser and immunotherapy combo takes on recurrent brain tumors
Disease control OngoingThis study tests a combination of laser heat therapy (LITT) and the immunotherapy drug pembrolizumab in 32 adults with recurrent glioblastoma, an aggressive brain cancer. The laser heats and destroys hard-to-reach tumors, while pembrolizumab helps the immune system fight cancer c…
Matched conditions: GLIOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Brain cancer breakthrough? new combo aims to shrink tumors in Hard-to-Treat glioblastoma
Disease control OngoingThis study tests whether adding a second chemotherapy drug, lomustine, to the standard treatment (temozolomide plus radiation) helps people with a specific type of glioblastoma live longer. The trial includes 265 adults with newly diagnosed tumors that have a methylated MGMT gene…
Matched conditions: GLIOSARCOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental trio therapy takes on recurrent glioblastoma
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs (INCAGN1876 and INCMGA00012) with targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer. The 39 participants receive the drugs before and after surgery to remove the tumor, pl…
Matched conditions: GLIOSARCOMA
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Promising combo targets deadliest brain tumors
Disease control OngoingThis study tests whether adding veliparib to the standard chemotherapy drug temozolomide helps people with a newly diagnosed, aggressive brain cancer called glioblastoma. The trial includes 447 patients whose tumors have a specific genetic change (MGMT promoter hypermethylation).…
Matched conditions: GLIOSARCOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New brain cancer drug shows promise in early trial
Disease control TerminatedThis early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receiv…
Matched conditions: GLIOSARCOMA
Phase: PHASE1 • Sponsor: Petrov, Andrey • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo therapy targets deadly brain cancer recurrence
Disease control OngoingThis early-stage trial tests whether combining a precise form of radiation (stereotactic radiosurgery) with two immunotherapy drugs (MBG453 and spartalizumab) is safe for people whose glioblastoma has come back. The study includes 16 adults with recurrent GBM. The main goal is to…
Matched conditions: GLIOSARCOMA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Ultrasound device opens brain barrier to attack deadly tumors
Disease control OngoingThis trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …
Matched conditions: GLIOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Brain cancer vaccine shows promise in early trial
Disease control OngoingThis phase II study tests a vaccine called SurVaxM, designed to train the immune system to attack glioblastoma cells, when given alongside standard chemotherapy (temozolomide). The trial includes 66 patients with newly diagnosed, survivin-positive glioblastoma or gliosarcoma. The…
Matched conditions: GLIOSARCOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Precision radiation boosts fight against deadly brain tumors
Disease control OngoingThis phase 2 trial tests whether giving a higher, more targeted dose of radiation—guided by advanced MRI scans—along with standard chemotherapy (temozolomide) can improve survival in 30 people with newly diagnosed glioblastoma, an aggressive brain cancer. The radiation is adapted…
Matched conditions: GLIOSARCOMA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy combo shows promise in tough brain cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 52 adults with this diagnosis will receive the combination therapy. The main goals are…
Matched conditions: GLIOSARCOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy drug takes on deadly brain cancer
Disease control OngoingThis early-stage trial tests the immunotherapy drug pembrolizumab in 60 adults with recurrent glioblastoma, an aggressive brain cancer. The study aims to see how the drug affects immune cells in the tumor and whether it is safe. Participants receive pembrolizumab before and after…
Matched conditions: GLIOSARCOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo shows promise in brain cancer battle
Disease control OngoingThis early-phase trial tests a new drug called selinexor alongside standard radiation and chemotherapy for people with newly diagnosed glioblastoma, a fast-growing brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with these treatments. A…
Matched conditions: GLIOSARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a simple MRI spot early success in brain cancer treatment?
Knowledge-focused OngoingThis study tests whether a special MRI scan, called DSC-MRI, can measure blood flow changes in brain tumors to predict if the drug bevacizumab is working early in treatment. Researchers will scan 146 patients with recurrent glioblastoma before and two weeks after starting the dru…
Matched conditions: GLIOSARCOMA
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Brain tumor tissue harvest aims to unlock genetic secrets
Knowledge-focused OngoingThis study collects multiple samples from different parts of a glioblastoma tumor during surgery. Researchers will analyze the samples to learn how genetic changes vary within a single tumor. The goal is to improve future diagnosis and treatment of brain tumors. The study involve…
Matched conditions: GLIOSARCOMA
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC